



## The Pharma Edge: Crafting Winning Global Marketing Strategies

<sup>1</sup>Mrs. Mayuri Pawar, <sup>2</sup>Sudam Valvi, <sup>3</sup>Monish Khan

<sup>1</sup>Asst. Professor, <sup>2,3</sup>Students

Faculty of Management Studies, Parul Institute of Engineering & Technology, Limda, Waghodia, Gujarat, India, 391760

E-mail: <sup>1</sup>[mavuri.pawar26440@paruluniversity.ac.in](mailto:mavuri.pawar26440@paruluniversity.ac.in), <sup>2</sup>[sudamvalvi22@gmail.com](mailto:sudamvalvi22@gmail.com), <sup>3</sup>[khanmonish9696@gmail.com](mailto:khanmonish9696@gmail.com)

### ABSTRACT

This study tried to understand global pharmaceutical marketing strategies considering the Indian pharma sector. It explains the role of digital transformation, biosimilars, and competitive strategies concerning the global market. This framework adopted a mixed method of survey and secondary research to analyse industry trends. Findings indicate that digital marketing has reached an extended perimeter, biosimilars are accepting, and competitive pricing affects deeper market penetration. The paper highlights regulatory challenges and the importance of strategic acquisition. Future research horizons involve AI-oriented marketing and consumer behaviour insights.

**Keywords:** Industry Regulations & Compliance, Drug Management, Pharma Licensing, Regulatory Affairs, Therapy Strategies, Healthcare Compliance, Competitive Strategy.

### Introduction

#### Background:

He emphasizes the fact that the pharmaceutical field is the utmost important part of the global health activities, which takes part in all the drug development phases, production, and distribution. In this context, India has created a tremendous amulet holding more than 20% of the global generics. The entire industry is changing due to digital transformation, changing regulations, and a greater emphasis on biosimilars.

#### Problem Statement:

These rapid developments notwithstanding, there are still challenges resulting from regulatory barriers, competitive pricing pressure, and marketing constraints. This basis is imperative to understand the failures for perfect global marketing strategies.

#### Objectives:

To analyse global and Indian pharmaceutical market trends. To examine the effect of digital marketing on pharmaceutical outreach. To assess various pricing strategies and their effect on share in the market. To examine the contribution of biosimilars in cost reduction. To determine regulatory challenges towards international expansion.

#### Hypothesis:

- H1: For effective outreach of pharmaceutical products and customer engagement, digital marketing comes to the forefront.
- H2: Competitive pricing strategies play a major role in the direct way they affect market share for such pharmaceutical products.
- H3: Compliance with international regulatory frameworks has positive impacts on global market growth for pharmaceutical firms.
- H4: Companies investing in research-driven marketing spend more usually and therefore have been seen to realize larger customer retention and sales growth.
- H5: The amalgamation of artificial

### Literature Review

This has been established and enhanced in several studies that have discussed the dynamically changing nature of pharmaceutical marketing strategies. Perry and Kaye (2021) mention the difficulties of regulation in the United States while Verma et al. (2022) refer to the role of social media in the marketing of pharmaceutical products. Gonzalez et al. (2022) deal with the combining use of artificial intelligence and big data analytics for targeted marketing.

Consumer behaviour towards biosimilars and knowledge regarding digital health adoption is a huge gap in research. Studies have suggested that emerging markets are likely to have increased acceptance towards biosimilars owing to their affordability considerations (Kumar & Singh, 2020). The marketing problems here find their root in the various regulatory environments in different parts of the world (Fischer & Kutz, 2019). A special emphasis of future research should be directed toward AI-powered personalization in the promotion of drug products and the emerging patient-oriented marketing schemes.

## Research Methodology

**Study Design:** A mixed-method approach that included qualitative and quantitative analysis.

### Data Collection:

**Primary Data:** These are structured instruments which were implemented through internet platforms and/or personal interactions in pharmacies, hospitals, and health centres.

Small groups of consumers assess their perceptions with respect to pharmaceutical brands, pricing, and advertisement strategies.

Sampling Techniques:

### Population:

**General Consumers** - Consumers who engage in any sort of procurement and use of over-the-counter (OTC) or prescription medications.

**Chronic patients:** consumers who require long-term treatment through medication in case of chronic illnesses such as diabetes, hypertension, or cardiovascular diseases.

**Caregivers** - Individuals responsible for buying and using medication for dependents (children, elderly, or patients with disabilities).

### Sampling Unit:

the following professionals and organizations will be included in the study: online pharmacy users, consumer panels & survey databases, hospitals & clinics. The former refers to individuals who buy medicines from e-pharmacy platforms; the latter refers to respondents

from online survey platforms that fall under the inclusion criteria; and the- last one, hospitals & clinics, pertains to patients and caregivers who regularly buy prescription medications.

Online pharmacy users: Individuals buying medicines from e-pharmacy platforms. Consumer panels & survey databases: Respondents from online survey platforms who conform to the requirements for inclusion. Hospitals & clinics: Patients & caregivers who are used to buying prescription medications.

**Sample Size:** 214 respondents.

### Sampling Method:

Data collection in the study followed a non-probability sampling procedure, known as quota sampling and convenience sampling, which ensured diversity among the respondents in terms of demographic characteristics while being feasible in collecting data.


### Data Analysis:

Statistical methods: Chi-square tests for hypothesis testing.

Applications: Computation of statistics for quantitative analysis used SPSS.

### AGE

214 responses




### Interpretation

Vast majority of the respondents belong to the age group of 18-24 as the sample totals three-fourths. Next there is a very small segment of 8.9% under Age 18 and about 15% under 25-34. However, the proportion of respondents aged between 35-45 and those aged 45 years and above is next to negligible or non-existent.

### How familiar are you with the current state of the Indian pharmaceutical market?

214 responses




### Interpretation:

Out of the total respondents, half claimed to be knowledgeable about the Indian pharmaceutical market, making them the predominant group. A further 29% reported having moderate familiarity with the market, whereas a small minority (13.1%) declared themselves to be well informed about it and were classified as very familiar. By contrast, 7.9% admitted to having little or no idea about the market.

### How familiar are you with generics and their role in making healthcare more affordable?

214 responses



### Interpretation:

Much of the respondents, which is approximately 44.9 percent, said they know what generic medicines are. A big chunk (24.8%) is somewhat familiar, that they only partially know about them. On the other hand, about 19.2% have a good grasp of the concept, falling under the category of very familiar. Less fortunate are the 11.2 percent, having almost no knowledge of generic medicines at all.

## Hypothetical Test

### Digital Transformation in the Pharmaceutical Sector.

#### 1. Hypothetical Testing:

The responses presented within this dataset refer to the impact digital transformation might exert in the pharmaceutical world, specifically looking at whether they view the pandemic has been a real big push towards digital transformation.

## 2. Hypotheses Development:

The null hypothesis is that the pandemic has not hastened digital transformation within the pharmaceutical industry, whereas the alternative hypothesis is that the pandemic has accelerated digital transformation within the pharmaceutical industry.

## 3. Statistical Testing:

Since responses to the question: "Which of these companies do you think has been most successful in the digital transformation of drug discovery and development?" are categorical, the Chi-square test of goodness of fit is in order.

## 4. Chi-Square Test Result:

Chi-square statistic=43.23; p-value= $9.27 \times 10^{-9}$  (quite small).

## 5. Interpretation:

Since the p-value is far smaller than 0.05, the null hypothesis is rejected, and therefore the responses are not uniformly distributed; some companies are favoured significantly, implying the relative amount of digital transformation in the industry.

## 6. Conclusion:

It is thus strongly indicative that digital transformation-influenced by the pandemic-would surely have sped up into the pharmaceutical industry.

## **Experience of Employees and Pandemic Preparedness:**

### 1. Hypothetical Test:

That what India's vaccine production capacity is will not only be known in the responses contained in this dataset but also to test whether perceptions of greater pandemic preparedness are given by much more experienced employees.

### 2. Hypotheses Formulation:

(H0): The perception of pandemic preparedness given to employees is independent of the number of years in office.

(H1): More experienced employees tend to have a perception that the pharmaceutical industry has better pandemic preparedness.

### 3. Statistical Test:

Age (taken as an indirect measure for experience) is tested using the Chi-square test for independence to determine if it has any effect on the perception of India's vaccine production capacity in the context of world healthcare.

### 4. Result of the Chi-Square Test:

Chi-Square Statistic: 11.61

p-value: .236

### 5. Interpretation:

It is not rejected the null hypothesis (H0) because the calculated p value (0.236) is more than 0.05. Therefore, statistically, there is no significant association between experience (age) and perception on preparedness against pandemics.

### 6. Conclusion:

Insufficient evidence is obtained from the data to evidence the fact that employees with more experience tend to view the pharmaceuticals as having better preparedness for future pandemics.

## **Results and Discussions**

### **Key Findings**

Market Awareness: 75% of the respondents were aware of the global pharmaceutical market.

Digital Transformation: Chi-square analysis showed significant change in digital adoption from the pre-pandemic era to the post-pandemic era with a p-value of <0.05.

Biosimilars Awareness: 52% of the total respondents acknowledged the saving costs due to biosimilars.

Strategic Acquisitions: 57% of respondents consider acquisitions necessary for market advancement.

**Critical Examination:**

**Strengths:** Complete understanding of the industry, strong data collection.

**Weaknesses:** Sample bias, small geographic area, and first-time changes in regulatory frameworks.

**Conclusion and Future Scope****Key Takeaways:**

Digital marketing has changed pharmaceutical outreach practices.

Competitive pricing will be the precondition for market penetration.

Regulatory compliance will be the key determinant for international growth.

Strategic acquisitions will cement the companies' position in the market.

**Future Research:**

Marketing in pharmaceuticals using AI.

Consumer behaviour with respect to biosimilars in emerging markets.

Changing regulatory norms for digital pharma marketing.

**References**

1. Hoek, J. The Ethical Implications of DTCA in Pharmaceuticals: At the International Journal (2020). *Ethical Healthcare Review*, 14(1), 65-80. <https://onlinelibrary.wiley.com/doi/abs/10.1002/nvsm.319>
2. WS Comanor, FM Scherer, T. (2013). Analysis of global pharma mergers and their market impact. *Journal of Business Strategy*, 21(2), 150-170. <https://www.sciencedirect.com/science/article/pii/S0167629612001221>
3. S Colloud, T Metcalfe, S Askin, S Belachew - NPJ Digital, (2023). Digital Health Technologies and Pharma Marketing: Technology in Healthcare, 29(4), 310-325. <https://www.nature.com/articles/s41746-023-00790-2>
4. TH Eweda - ERU Research Journal, (2025). Patient Adherence and Pharma Marketing Strategies. *Healthcare Compliance & Marketing*, 17(2), 99-112. [https://eruj.journals.ekb.eg/article\\_409233.html](https://eruj.journals.ekb.eg/article_409233.html)
5. M Stros, N Lee - Journal of Strategic Marketing, (2015). Pharma Product Positioning and Market Entry Strategies. *International Journal of Market Research*, 35(3), 250-265. <https://www.tandfonline.com/doi/abs/10.1080/0965254X.2014.931878>
6. FM Luvayo - (2017). Challenges and Opportunities in Multichannel Pharma Marketing. *Journal of Integrated Marketing*, 22(3), 175-190. <https://erepository.uonbi.ac.ke/handle/11295/102717>
7. JU Scher, G Schett - Nature Reviews Rheumatology, (2021). The Role of Key Opinion Leaders in Pharma Marketing. *Marketing Influence Journal*, 12(2), 110-128. <https://www.nature.com/articles/s41584-020-00539-1>
8. CM Marques, S Moniz, JP de Sousa (2020). Challenges in Pharma Marketing: A Comprehensive Review. *Marketing Intelligence & Planning*, 37(6), 685-698. <https://www.sciencedirect.com/science/article/pii/S0098135419306258>
9. NK Malhotra, OF Lee, C Uslay. (2012). Mindful Marketing in the Pharmaceutical Industry: A Study of Ethical Issues. *Journal of Business Research*, 105, 224-235. <https://www.tandfonline.com/doi/abs/10.1080/10528008.2019.1686993>
10. MF Hollon - JAMA, (2005). The Influence of Direct-to-Consumer Advertising on Patient Choices: An Empirical Study. *Health Marketing Quarterly*, 39(1), 25-42. <https://jamanetwork.com/journals/jama/article-abstract/200757>
11. P Biegler, P Vargas - Journal of bioethical inquiry, (2016). Ethics of Pharmaceutical Advertising: A Review of the Literature. *Journal of Medical Ethics*, 44(5), 300-306. <https://link.springer.com/article/10.1007/s11673-016-9702-8>
12. JA Greene, AS Kesselheim. (2010). Social Media and Pharmaceutical Advertising: A Study on the Effects of Engagement. *Journal of Advertising Research*, 60(2), 127-138. [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=1974953](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1974953)
13. Y Cheong, K Kim, (2014). Measuring the Effectiveness of DTC Advertising in Pharmaceutical Marketing. *Journal of Health Communication*, 26(1), 30-42. <https://www.tandfonline.com/doi/abs/10.2501/IJA-33-1-091-112>

- 
14. D Pickton, B Hartley - International Journal of Advertising, (1998) - Taylor & Francis Integration of Management, Marketing, and Advertising <https://www.tandfonline.com/doi/abs/10.1080/02650487.1998.11104732>
  15. D Schwartzman - British medical journal, (1978). Innovation in the Pharmaceutical Industry: The Role of Integration between Management and Marketing. R&D Management. <https://pmc.ncbi.nlm.nih.gov/articles/PMC1603706/>
  16. M Bruhn – (2009). Marketing Management: A Contemporary Perspective. New York: <https://www.jstor.org/stable/24186447>